Dynavax Technologies (DVAX) Stock Price, News & Analysis

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DVAX shares.
View DVAX analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12 month target prices for Dynavax Technologies' stock. Their DVAX share price targets range from $20.00 to $28.00. On average, they predict the company's share price to reach $25.00 in the next year. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts.

Dynavax Technologies' stock was trading at $13.98 at the beginning of 2024. Since then, DVAX shares have decreased by 15.6% and is now trading at $11.80.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our DVAX earnings forecast.

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company had revenue of $108.27 million for the quarter, compared to the consensus estimate of $77.30 million. Dynavax Technologies had a negative net margin of 2.75% and a negative trailing twelve-month return on equity of 1.08%. During the same quarter last year, the business posted ($0.15) earnings per share.

ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).First Trust Small Cap Growth AlphaDEX Fund (FYC).

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Dynavax Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.18%), Allspring Global Investments Holdings LLC (0.11%) and Diversified Trust Co (0.02%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.